Skip to main content
. 2020 Apr 23;5(8):e136907. doi: 10.1172/jci.insight.136907

Figure 1. GLP-2 treatment does not alter glucose and lipid metabolism in HFHC diet–fed mice.

Figure 1

Metabolic endpoints in mice with diet-induced NAFLD treated with GLP-2. (A) Seven- to eight-week-old WT male mice were allocated to HFHC or control diet (CD) for 17 weeks and then treated with h[Gly2]GLP-2 (0.1 mg/kg BID) or vehicle for the last 11 days on diet (n = 9–10 per group for all panels). (B) Body weight gain. (C) i.p. glucose tolerance in 5- to 6-hour fasted mice after 5 days of GLP-2 or vehicle and area under curve (AUC) 0–120 minutes. (D and E) Plasma lipids at the end of study. TG, triglycerides. (F) Representative Oil Red O staining of liver sections (scale bar: 100 μm) and quantification of Oil Red O–positive staining in liver. (G) Hepatic cholesterol and TG content. (H) Hepatic mRNA abundance, relative to Ppia, of genes relevant to lipid metabolism pathways. Data are presented as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, §P < 0.05, significant effect of diet on total variance, using 2-way ANOVA with Tukey correction for multiple comparisons.